Novo Nordisk to present new data highlighting innovative rare blood disorders pipeline at ASH 2024
Clinical data include analyses of novel, investigational therapies with the potential to help address unmet needs in sickle cell disease and hemophiliaNew data from the HIBISCUS phase 2 trial evaluating